Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/18053
Title: Early viral-specific T-cell testing predicts late cytomegalovirus reactivation following liver transplantation.
Austin Authors: Sood, Siddharth ;Haifer, C;Yu, L;Pavlovic, J ;Gow, Paul J ;Jones, Robert M ;Visvanathan, Kumar;Angus, Peter W ;Testro, Adam G 
Affiliation: Victorian Liver Transplant Unit, Austin Health, Heidelberg, Victoria, Australia
Department of Gastroenterology & Hepatology, Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia
Innate Immune Laboratory, St Vincent's Hospital, University of Melbourne, Melbourne, Victoria, Australia
Issue Date: 29-May-2018
metadata.dc.date: 2018-05-29
Publication information: Transplant infectious disease : an official journal of the Transplantation Society 2018; 20(5): e12934
Abstract: Although antiviral prophylaxis is effective in preventing early cytomegalovirus (CMV) reactivation following liver transplantation (OLT), it predisposes patients to late CMV after prophylaxis has ceased. QuantiFERON-CMV (QFN-CMV, Qiagen, The Netherlands) measures an individual's viral-specific immune response. Fifty-nine OLT recipients were prospectively monitored post-OLT in an observational cohort study. QFN-CMV was performed at regular time-points. An absolute QFN-CMV <0.1 IU/mL was considered non-reactive. 50/59 (84.7%) had a reactive QFN-CMV by M6. 38/59 (64.4%) had antiviral prophylaxis or treatment before M6, with 31/38 (81.6%) developing a reactive QFN-CMV by 6 months. Over 90% already had a reactive result as early as 3 months post transplant, 3 patients (5.08%) developed late CMV between 6-12 months (median 251 days)-all had a non-reactive M6 QFN-CMV. And 2/3 experienced CMV disease. Non-reactive M6 QFN-CMV was significantly associated with late CMV (OR = 54.4, PPV = 0.33, NPV = 1.00, P = .003). Although only 5% of recipients developed late CMV, 2/3 suffered CMV disease. M6 QFN-CMV has an excellent NPV for late CMV, suggesting patients who exhibit a robust ex vivo immune response at M6 can safely cease CMV monitoring. Furthermore, >90% already express viral-specific immunity as early as 3 months. Conceivably, antiviral prophylaxis could be discontinued early in these patients.
URI: http://ahro.austin.org.au/austinjspui/handle/1/18053
DOI: 10.1111/tid.12934
ORCID: 0000-0002-9341-4792
PubMed URL: 29809312
Type: Journal Article
Subjects: CMV disease
QFNCMV
cytomegalovirus
late CMV
liver transplantation
quantiferon-CMV
Appears in Collections:Journal articles

Show full item record

Page view(s)

10
checked on Mar 2, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.